Convertible note vs SAFE in 2026: which to use and when

The default in 2026 is simple: post-money SAFE for US Delaware C-corps raising under about $3M from sophisticated angels and institutional seed funds; convertible note for everything else. Use the table below as the starting point, then read for the four edge cases that flip the call. The instrument is rarely what makes or breaks the round, but picking the wrong one costs founders dilution and lawyer time.

For ten years, the convertible note vs SAFE debate has been where smart founders waste two weeks. The truth is that the choice has become much narrower than the debate suggests, and the right answer is usually visible in the first 90 seconds if you know what you're looking at. This guide is the framework I use when seed founders ask me which instrument to pick — and the four scenarios where the default is wrong.

The TL;DR is in the table. The teardown that follows is for when the table doesn't fit your situation cleanly.

The 30-second comparison

The whole rest of this guide is the founder's-perspective version of why each row is what it is, and which edge cases force you off the default.

What changed in 2026 (and what didn't)

Three things drifted in the last 18 months:

Post-money SAFE is now the actual standard, not just the most-talked-about template. YC's post-money SAFE shipped in 2018 and the rest of the market took until about 2024 to fully migrate. As of 2026, every reputable seed-stage law firm — Cooley, Gunderson, WSGR, Orrick, Fenwick — defaults to it. If a lead investor proposes a pre-money SAFE, that's a 2018-era choice and worth flagging.

The "SAFE doesn't work outside the US" objection has gotten quieter, but not gone. Carta, Stripe Atlas, and Clerky routinely issue SAFEs for non-Delaware entities now, and a few non-US jurisdictions (UK, Singapore, France) have built enough case law that local SAFE variants are credible. But the moment you're in a market where SAFE precedents haven't been tested in court — most of LATAM, parts of MENA, parts of Asia outside Singapore — convertible notes still win because note law is universal and SAFE law isn't.

Convertible notes have come back at the high end. When a seed round breaks $3M+ and pulls in a sophisticated institutional lead, the lead increasingly prefers a convertible note because the cap-table math at conversion is cleaner and the maturity date imposes a discipline that lead investors appreciate. This isn't a fashion shift; it's pure mechanics. We'll cover it under "edge case 2" below.

The post-money SAFE in plain English

A post-money SAFE is an agreement that gives the investor the right to receive shares at a future priced round, on terms set today. The standard YC version has two negotiable knobs: the valuation cap and the discount. The investor gets the more favorable of the two at conversion.

What's "post-money" mean? At conversion, the cap is interpreted as the company's valuation after all SAFEs convert and the priced round closes. This sounds like jargon, but the practical consequence matters: stacking multiple SAFEs at the same cap dilutes the founders predictably, not the earlier investors. With pre-money SAFE, every new SAFE stealth-diluted the prior ones, which led to surprise founder dilution at conversion.

In 2026, "post-money" is the only version a sophisticated investor will accept and the only version a competent seed lawyer will draft. Anything else is a tell about who you're dealing with.

The standard cap and discount values for seed rounds in 2026:

• Cap: typically $8M-$15M for seed, lower for pre-seed.
• Discount: typically 10-20%, with 20% being the most common.
• MFN (Most Favored Nation) clause: usually present, often abused. Worth its own guide on MFN clauses.

The convertible note in plain English

A convertible note is a loan that converts to equity at a future priced round. Because it's a loan, it has interest (usually 5-8%/year) and a maturity date (usually 18-24 months out). At conversion, the principal plus accrued interest convert into shares at the more favorable of: a valuation cap, or a discount to the next round's price.

Mechanically, a convertible note does almost the same job as a SAFE. The substantive differences come from the loan structure:

• Interest accrues — at conversion, the investor gets shares for principal + interest, which is slightly more dilutive than a SAFE at the same cap.
• Maturity date — if no priced round happens before maturity, the note technically becomes due. In practice, almost nobody enforces this; it gets extended or amended. But the mere existence of maturity creates a deadline-driven discipline that some leads want.
• Default rights — convertible notes can include events of default, which give the investor leverage in extreme scenarios. SAFEs don't.

For founders, the practical difference is: more lawyer time per check, slightly more dilution, slightly more downside risk, but a structure that some sophisticated leads insist on.

The four edge cases that flip the default

If your situation matches any of the four below, the SAFE default is wrong and you should default to a convertible note instead.

Edge case 1: you're not US Delaware-incorporated

If your entity is incorporated in a jurisdiction where SAFE precedents are thin (most of LATAM, Africa, Eastern Europe, Asia outside Singapore), a SAFE might convert in a way you don't expect because local court interpretation is untested. Convertible notes use loan-law primitives that exist in every jurisdiction; a local lawyer can give you confident answers.

The exception inside this exception: UK, Singapore, France, and Germany have all developed enough case law in 2024-2026 that local SAFE variants (or "ASA" — Advanced Subscription Agreement, in the UK) are now credible. If you're in one of those four, default back to SAFE.

Edge case 2: you're raising more than ~$3M

The post-money SAFE math gets weird above about $3M because of how cap interpretation interacts with the priced round's structure. Specifically, the more SAFEs stacked at different caps, the harder it is to model dilution accurately, and the priced-round modeling becomes a multi-day exercise that lawyers charge for.

Convertible notes convert through a more standard mechanism that a tier-2 lawyer can model in 20 minutes. At $3M+ raise sizes, that simplification is worth real money — both in fees saved and in not surprising your future Series A lead.

Edge case 3: your lead is a credit-leaning institution (not a fund)

Some institutional investors — particularly family offices, corporate VC arms, and a few European sovereign wealth funds — have credit teams whose default reflex is "we lend, we don't gift." Those institutions can deploy $1-5M into a startup but prefer the loan structure of a convertible note. They don't want a SAFE; they want interest and a maturity date as basic stewardship.

If your lead is one of those, fight the SAFE battle is futile. Take the convertible note, negotiate the interest down to 5%, and move on. The 2-3% extra dilution is worth less than two weeks of negotiation friction.

Edge case 4: you have a regulatory reason to use debt

Some specific situations — government-grant cofunding rules in the EU, certain CFIUS-flagged scenarios in the US, a few corporate-investor compliance regimes — require the investment to be debt-classified at the time of investment. SAFE is famously neither debt nor equity ("convertible securities" is its own bucket); convertible notes are unambiguous debt. If you've been told by counsel that the investment must be debt at signing, take the note.

This is rare. If your lawyer hasn't specifically said "must be debt," you don't have this case.

The negotiation knobs that actually matter

Founders spend too much time arguing about the wrong terms. The four that meaningfully affect dilution and downstream optionality:

The cap. This is the dominant variable. Every dollar of cap difference is dollars of dilution at conversion. Negotiate this hard. The discount, by comparison, is a rounding error in most rounds.

MFN scope. A wide MFN clause means a single later investor at a lower cap pulls every prior SAFE down to that cap automatically. Tight scope (or no MFN) is much friendlier to founders — but rare to negotiate out completely. More on MFN clauses.

Conversion mechanics on partial closes. Some SAFEs and notes have ambiguous language about what happens if the next round is unpriced (another SAFE round) or partial. Have your lawyer confirm the conversion path for both the priced-round and not-yet-priced cases.

Pro-rata rights. A pro-rata clause gives the investor the right to participate in future rounds at the same percentage. Almost always negotiated. Worth giving to lead investors at seed; usually pushed back on for follow-on angels.

The discount, the interest rate, the maturity date — these matter, but they're not where you spend negotiation capital. Cap and MFN are.

How to actually run a multi-investor close in 2026

The mechanics that founders most often get wrong:

1. Pick one instrument and one cap before opening the round. Negotiating the cap with each investor individually is how rounds take six months. Set the cap, lock the SAFE template, and tell every check the same number.
2. Use Carta or Clerky to send identical paperwork. Hand-rolled DocuSigns are how you accidentally end up with eight subtly-different SAFEs and a $30K legal cleanup at Series A.
3. Run a real first close at 30-50% of the target. A real close locks the cap and unblocks subsequent checks. Trying to close every investor simultaneously is how rounds drift.
4. Be honest about the cap to every investor. "We're at $X cap, here's the SAFE" is the right opener. "We're at $X cap with you, but $Y cap with someone else" leaks within a week and torches trust.
5. Get the lead's papers signed first. Once the lead is signed, every subsequent check moves twice as fast.

When this decision is genuinely binary

Most of the time, founders agonize over a decision that doesn't materially change the outcome. The instrument is fungible at the margins. What matters far more is:

• Closing the round (any round) at a cap that gives you 18+ months of runway
• Picking a lead whose follow-on capital you'd actually want
• Not screwing up MFN scope or pro-rata rights at signing

Pick the default in the table above unless you hit one of the four edge cases. Spend your real negotiation effort on the cap. Use the time you save on customer conversations.

When this matters for your raise

Pick the wrong instrument and you'll lose two weeks and possibly 1-2% of your cap table. Pick the right one and the round closes faster and the Series A lawyer doesn't make weird faces at your paperwork. The decision is rarely make-or-break — but the time it consumes when wrong is exactly the time you don't have during a raise.

If you're 60-90 days from opening your round, Causo handles the partner targeting and outreach mechanics so you can concentrate the legal work on the round itself. Built by founders who've signed both kinds of paper. Start free.